Delivery Order SPE2DB24D2101-SPE2DB25FKNMM
- Not listed
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $42,518.73 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on August 14, 2025, with completion targeted for August 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, reflecting the broad...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (16 count) with a contract ceiling value of $4,734.66. This is a firm fixed-price delivery order with an ultimate completion date of August 7, 2025, representing a competitively awarded contract with no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packs of 10, with a ceiling value of $8,505.23. This is a firm fixed-price delivery order with an ultimate completion date of September 18, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency awarded a $15,567.60 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of UBRELVY 100 mg tablets (unit dose, 10s). This is a firm fixed price, competitively awarded contract with an ultimate completion date of August 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a prescription migraine treatment, indicating this delivery order supports military or federal...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of UBRELVY 100 mg tablets (16 unit dose packaging) with a ceiling value of $9,128.76. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was competitively procured with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.96 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose packages) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- The Defense Logistics Agency awarded a delivery order valued at $1,860.47 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16 unit dose packets) on August 4, 2025, with completion scheduled for August 5, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. UBRELVY is a migraine treatment medication, and the award reflects the company's role as a critical pharmaceutical supplier to federal medical procurement needs. The place of performance...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKNMMDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (16 units) with a ceiling value of $3,810.32. This delivery order is a firm fixed price contract with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for ultimate completion by August 15, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine medication, reflecting the company's role in supplying specialized pharmaceutical products to support federal healthcare requirements. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems through this global framework agreement, which enables the company to supply brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 8/14/25 |